Clinical significance of metastatic-tumor HER2 status in patients with HER2-positive primary breast cancer

被引：0
|
作者：
Niikura, N.
Liu, J.
Hayashi, N.
Mittendorf, E. A.
Gong, Y.
Palla, S. L.
Tokuda, Y.
Gonzalez-Angulo, A. M.
Hortobagyi, G. N.
Ueno, N. T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Tokai Univ, Sch Med, Kanagawa 2591100, Japan
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
545
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Margetuximab in HER2-positive metastatic breast cancer
    Gradishar, William J.
    O'Regan, Ruth
    Rimawi, Mothaffar F.
    Nordstrom, Jeffrey L.
    Rosales, Minori K.
    Rugo, Hope S.
    FUTURE ONCOLOGY, 2023, 19 (16) : 1099 - 1112
  • [32] Therapy for HER2-Positive Metastatic Breast Cancer
    Dekker, Tim J. A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (25):
  • [33] Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
    Fehm, Tanja
    Becker, Sven
    Duerr-Stoerzer, Silke
    Sotlar, Karl
    Mueller, Volkmar
    Wallwiener, Diethelm
    Lane, Nancy
    Solomayer, Erich
    Uhr, Jonathan
    BREAST CANCER RESEARCH, 2007, 9 (05) : R74
  • [34] Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
    Tanja Fehm
    Sven Becker
    Silke Duerr-Stoerzer
    Karl Sotlar
    Volkmar Mueller
    Diethelm Wallwiener
    Nancy Lane
    Erich Solomayer
    Jonathan Uhr
    Breast Cancer Research, 9
  • [35] Loss of HER2 expression in HER2-positive breast cancer patients after neoadjuvant therapy
    Sang, Yuting
    Wu, Jiong
    Yang, Benlong
    CANCER RESEARCH, 2022, 82 (04)
  • [36] Incorporating Neratinib Into Clinical Practice for Patients With HER2-Positive Metastatic Breast Cancer
    Isaacs, Claudine
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 12 - 15
  • [37] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [38] Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients
    Maria, Alaa Mohamed
    El-Shebiney, Mohamed
    El-Saka, Ayman Mohamed
    Zamzam, Yomna
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2018, 30 (02) : 49 - 55
  • [39] Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients:: a clinical study
    Carabantes-Ocon, F.
    Saez-Lara, E.
    Burgos-Garcia, L.
    Villar-Chamorro, E.
    Casaus-Hazanas, A.
    Luna, S.
    Martinez, C.
    BREAST CANCER RESEARCH, 2007, 9 (01)
  • [40] HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer
    Hosonaga, Mari
    Arima, Yoshimi
    Sampetrean, Oltea
    Komura, Daisuke
    Koya, Ikuko
    Sasaki, Takashi
    Sato, Eiichi
    Okano, Hideyuki
    Kudoh, Jun
    Ishikawa, Shumpei
    Saya, Hideyuki
    Ishikawa, Takashi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (08)
12345